ClinicalTrials HQ

Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy

Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy

Recruiting · NCT07075016 · Registry updated 2025-08-19
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive ChemotherapyHemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasmRecruitingPhase 32025-08-19NCT07075016

8 results · Page 1 of 1

119 results · Page 1 of 5

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
AT-Feldkirch-IKHFFeldkirchAustria2
AT-Salzburg-SALKSalzburgAustria3
AT-Vienna-HANUSCHViennaAustria4
BE-Antwerpen-ZASAntwerpBelgium3
BE-Brussel-BORDETBrusselsBelgium5
BE-Brussel-UZBRUSSELBrusselsBelgium3
BE-Bruxelles-STLUCBrusselsBelgium7
BE-Gent-UZGENTGhentBelgium7
BE-Leuven-UZLEUVENLeuvenBelgium10
BE-Liege-CHULIEGELiègeBelgium5
BE-Yvoir-MONTGODINNEYvoirBelgium5
CH-Basel-USBBaselSwitzerland5
CH-Bellinzona-IOSIBellinzonaSwitzerland5
CH-Bern-INSELBernSwitzerland6
CH-Zurich-USZZurichSwitzerland1
DE-Berlin-CAMPUSBENFRANKLINBerlinGermany4
DE-Berlin-CAMPUSVIRCHOWBerlinGermany4
DE-Berlin-VIVANTESNEUKOLLNBerlinGermany4
DE-Bochum-RUBBochumGermany5
DE-Bonn-UNIBONNBonnGermany5
DE-Braunschweig-KLINIKUMBRAUNSCHWEIGBraunschweigGermany5
DE-Bremen-KBMBremenGermany4
DE-Darmstadt-KLINIKUMDARMSTADTDarmstadtGermany3
DE-Flensburg-MALTESERFlensburgGermany4
DE-Freiburg-UNIKLINIKFREIBURGFreiburg im BreisgauGermany3